FDA Approves Dabrafenib and Trametinib for BRAFV600E-mutant NSCLC

Share this content:
The US Food and Drug Administration approved the combination of dabrafenib and trametinib for metastatic non–small cell lung cancer (NSCLC) with a BRAFV600E mutation.
The US Food and Drug Administration approved the combination of dabrafenib and trametinib for metastatic non–small cell lung cancer (NSCLC) with a BRAFV600E mutation.

The US Food and Drug Administration (FDA) approved the combination of dabrafenib and trametinib for metastatic non–small cell lung cancer (NSCLC) with a BRAFV600E mutation. This is the first time the FDA has approved treatments specifically for BRAFV600E-positive metastatic NSCLC.

Also approved was the Oncomine Dx Target Test, a next-generation sequencing (NGS) test to detect the presence of BRAF, ROS1, and EGFR gene mutations, as well as changes in tumor tissue.

The FDA based its approvals on the results from Study BRF113928 (ClinicalTrials.gov Identifier: NCT01336634), an international, multicenter, 3-cohort, non-randomized, non-comparative, open-label trial that enrolled 93 patients with BRAFV600E-positive NSCLC.

Fifty-seven patients were previously treated with a platinum-based chemotherapy regimen and 36 were treatment naïve.

In previously treated patients, the overall response rate (ORR) was 63% (95% CI: 49%-76%) and the median duration of response (DoR) was 12.6 months (95% CI, 5.8-not estimable). The ORR in the treatment naïve group was 61% (95% CI: 44%-77%) and median DoR was not estimable (95% CI, 6.9-NE).

Patients who received single-agent dabrafenib had an ORR of 27% (95% CI: 18%-38%) and median DoR of 9.9 months. The ORR was determined by an independent review committee.

Treatment should be initiated only once the BRAFV600E mutation is confirmed by an FDA-approved test.

RELATED: First-line Nivolumab Fails To Prolong Survival in Stage IV NSCLC

The recommended dosages are trametinib 2 mg once daily and dabrafenib 150 mg every 12 hours.

The most commonly observed adverse reactions (occurring in at least 20% of patients) were nausea, vomiting, diarrhea, decreased appetite, pyrexia, fatigue, edema, chills, cough, dyspnea, dry skin, rash, and hemorrhage.  

Reference

  1. FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation [news release]. Silver Spring, MD: US Food and Drug Administration; June 22, 2017. https://www.fda.gov/Drugs/InformationOnDrugs/ ApprovedDrugs/ucm564331.htm. Accessed June 22, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters